Most companies working on immune reset are focused on depleting the B cells that drive autoimmune disease. ai3Bio, a startup covered by MedCity News, is taking a different approach: it aims to reset the immune system by targeting inflammatory T cells. The company's initial focus is autoimmune liver diseases, an area where patients have few, if any, treatment options.
The startup's science centers on inflammatory T-cell biology, including Th17 cells and IL-17 signaling, and also involves the cGAS-STING pathway. By selectively addressing these T cells, ai3Bio hopes to offer a new way to treat chronic inflammation without the broad immune suppression associated with current therapies.
Because the report covers only ai3Bio, there is no independent comparison to other immune-reset programs. Still, the company's shift from B cells to T cells marks a distinct bet in a field that has largely concentrated on B-cell depletion.